AGEN Quote, Financials, Valuation and Earnings

Kura Oncology has a net margin of -170.88% compared to Agenus's net margin of -407.07%. Agenus's return on equity of -- beat Kura Oncology's return on equity of --.

Agenus has a consensus price target of $6.00, signalling upside risk potential of 106.19%. On the other hand Kura Oncology has an analysts' consensus of $26.25 which suggests that it could grow by 355.73%. Given that Kura Oncology has higher upside potential than Agenus, analysts believe Kura Oncology is more attractive than Agenus.

Agenus has a beta of 1.476, which suggesting that the stock is 47.645% more volatile than S&P 500. In comparison Kura Oncology has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.853%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kura Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Kura Oncology pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Kura Oncology quarterly revenues of $14.1M. Agenus's net income of -$45.9M is higher than Kura Oncology's net income of -$57.4M. Notably, Agenus's price-to-earnings ratio is -- while Kura Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.47x versus -- for Kura Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -170.88% compared to Agenus's net margin of -2.16%. Agenus's return on equity of -- beat Myomo's return on equity of -48.64%.

Agenus has a consensus price target of $6.00, signalling upside risk potential of 106.19%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 182.81%. Given that Myomo has higher upside potential than Agenus, analysts believe Myomo is more attractive than Agenus.

Agenus has a beta of 1.476, which suggesting that the stock is 47.645% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Myomo quarterly revenues of $12.1M. Agenus's net income of -$45.9M is lower than Myomo's net income of -$260.1K. Notably, Agenus's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.47x versus 3.71x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -170.88% compared to Agenus's net margin of -63.22%. Agenus's return on equity of -- beat Nuwellis's return on equity of -800.59%.

Agenus has a consensus price target of $6.00, signalling upside risk potential of 106.19%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1214.73%. Given that Nuwellis has higher upside potential than Agenus, analysts believe Nuwellis is more attractive than Agenus.

Agenus has a beta of 1.476, which suggesting that the stock is 47.645% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.478%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Nuwellis quarterly revenues of $2.3M. Agenus's net income of -$45.9M is lower than Nuwellis's net income of -$1.5M. Notably, Agenus's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.47x versus 0.18x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -170.88% compared to Agenus's net margin of 35.65%. Agenus's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Agenus has a consensus price target of $6.00, signalling upside risk potential of 106.19%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 743.02%. Given that Protalix BioTherapeutics has higher upside potential than Agenus, analysts believe Protalix BioTherapeutics is more attractive than Agenus.

Agenus has a beta of 1.476, which suggesting that the stock is 47.645% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

Agenus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Agenus quarterly revenues are $26.8M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Agenus's net income of -$45.9M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Agenus's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 57.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus is 0.47x versus 2.67x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.